Member Info for Propinquity

Profitable mining from day one
Potential dividends
Self-funded diversification into other minerals
And free shares in Calidus

Seriously, what's not to like? Now is the time to buy before it rockets...

Just over two days to go - at the latest - before we receive:

'Keras anticipates that the all documentation related to the Exploitation Permit will be signed by SGM and Keras during the course of the current week, and a full announcement of the terms of the Permit and the underlying protocols will be made immediately after signature.'

The future looks rosy...

...just a few things to clarify to the market:

Contract signed between KRS and its Togolese subsidiary for the mining-licence
Publish the details of whatever type of off-take or JV agreement will be for the manganese
Confirm the finer details of the CAI share-disbursement to the qualifying KRS shareholders
Strategy for developing, and diversifying into, other highly sought-after minerals

Feel free to add/delete to the above-list.

For that to happen, a few things to clarify to the market:

Contract signed between KRS and its Togolese subsidiary for the mining-licence
Publish the details of whatever type of off-take or JV agreement will be for the manganese
Confirm the finer details of the CAI share-disbursement to the qualifying KRS shareholders
Strategy for developing, and diversifying into, other highly sought-after minerals

Feel free to add/delete to the above-list.

A pleasant chap - yes, and missing him both here and on SML.

Andee, I completely forgot - wondering what all the unusually positive posts were about.

Expect it to break the 0.5 - 0.6 resistance-range when the RNS is released on the signing between KRS and its Togolese subsidiary.

Davidious, How very dare you counter the adverse adverse commenters?

Realist or irrational pessimist - more likely the latter.

Davidious, His invidious deliberations are best ignored.

Wishey, Thanks - and agreed; based on what I have read, I'd imagine that around this time next year, this will be closer to a £1 - or over it.

Davidious, Nail on head - all about market psychology - the MMs' digitally incanting their bewitchingly negativus sentimentum spell over those who fail to recognise that this remains still a fundamentally good business. And, of course, the MMs' modus operandi is buttressed by posters like djryan, who childishly write rantings and ramblings, primarily because they overbought.

Look at you two lovebirds' chirping away at each other.

Significant piece from the interims:

'I am also delighted to report that the collaboration and license deal established with Professor Bill Bachovchin of Tufts University Medical School is progressing very well. The opportunity to test the tumour targeting chemistry in the clinic as early as next year is well ahead of schedule and could be game-changing for Avacta. Doxorubicin is a $1bn drug despite severe cardiotoxicity issues that limits its effectiveness. In the case of Avacta's improved version of this drug, AVA6000 pro-Doxorubicin that is based on the Tufts technology, we have seen a dramatic improvement in safety in pre-clinical animal models. If we see a similar reduction in cardiotoxicity in humans in the planned phase I clinical trial of AVA6000 in 2020, then there is the potential for a major license deal that could generate a transformational, non-dilutive, upfront payment of tens of millions of dollars. This funding would support all our other programmes in future. We should also be able to apply the Tufts technology to improve the safety of a large number of other established chemotherapies and generate similar licensing opportunities. For this reason, we are prioritising this programme with respect to use of the proceeds of today's successful placing.'

Why on earth does this one keep falling? I have been invested in this one for many years - it's the cliched bottom-drawer for me.

MrT, One could argue that the Cobre situation has been resolved in so far as that yearly revenue remains on track to return to normal - without the the major client's contribution, of course - with said client and SML scheduled for arbitration in an attempt to compensate the latter; now, I have personally anticipated - for my sanity - that SML will receive nothing from it; if the claim is successful, then it's a bonus.

Pablo, Very kind of you. Yes, the gerund - a controversial actor in the English language.

Good call, Gorsuch.

Couldn't agree more, Surprised - which is I am a more-profitable mid- to long-term investor than a short-term trader.

Markyess, The contrastingly combined characteristics of your eagle-eyed thoroughness and your auguring convey you as quite a formidable investor - a pleasure to be on your side.